Teva Pharmaceutical Industries Limited cash flow to debt ratio of 9.49% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Teva Pharmaceutical Industries Limited's free cash flow has increased 53.27% from $749.00M last year to $1.15B, signaling increasing performance

Teva Pharmaceutical Industries Limited's debt to equity ratio is 2.16, which means that the company's assets are unhealthy financed, signaling financial risk.

Teva Pharmaceutical Industries Limited's debt has decreased relative to shareholder equity from 3.36 last year to 2.16 today, signaling strengthened financials

Teva Pharmaceutical Industries Limited has a net debt to EBITDA ratio of 4.40x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

Teva Pharmaceutical Industries Limited's interest coverage ratio of 2.99 indicates that earnings with margin can cover interest payments on company debt

Teva Pharmaceutical Industries Limited's profit margin was -9.91% last year and is 4.12% this year, signaling increasing performance

Teva Pharmaceutical Industries Limited's short-term assets of $13.95B exceed its short-term liabilities of $13.46B

Teva Pharmaceutical Industries Limited's return on assets of 1.80% is lower than the 5.00% threshold, indicating inefficient asset utilization

Teva Pharmaceutical Industries Limited's return on equity of 9.18%, is lower than 15.00%, indicating bad performance

Teva Pharmaceutical Industries Limited's operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Teva Pharmaceutical Industries Limited had positive net income in only 2 out of 5 years, indicating unstable earnings

Teva Pharmaceutical Industries Limited has positive free cash flow, indicating the company generates cash after capital expenditures

Teva Pharmaceutical Industries Limited has a free cash flow yield of 2.37%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Teva Pharmaceutical Industries Limited's yearly earnings has increased 186.03% since last year from $-1.64B to $1.41B, signaling increasing performance

Teva Pharmaceutical Industries Limited's yearly revenue has increased 4.32% since last year from $16.54B to $17.26B, signaling increasing performance

ROIC 9.00% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

Teva Pharmaceutical Industries Limited's 3-year revenue CAGR of 4.96% is positive, indicating growing revenue over the past 3 years

Teva Pharmaceutical Industries Limited had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Teva Pharmaceutical Industries Limited had positive ROE in only 2 out of 5 years, indicating inconsistent returns on equity

Teva Pharmaceutical Industries Limited is overvalued relative to its fair value price of 20.41 based on Base Cash Flow Valuation (DCF) model

Teva Pharmaceutical Industries Limited has an earnings yield of 1.48%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Teva Pharmaceutical Industries Limited is overvalued relative to its fair value price of 6.96 based on Base EBITDA Valuation model

Teva Pharmaceutical Industries Limited has an EV/EBITDA ratio of 19.80x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Teva Pharmaceutical Industries Limited is overvalued relative to its fair value price of 4.05 based on Base Earnings Fair Value model

Teva Pharmaceutical Industries Limited had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Teva Pharmaceutical Industries Limited has a price-to-book ratio of 6.23x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Teva Pharmaceutical Industries Limited has a price-to-sales ratio of 2.78x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue